Company intelligence / Profile preview

Heart Regeneration Technologies

Innsbruck, Tyrol, Austria

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Low-energy shockwave therapy for cardiac regeneration has demonstrated safety and efficacy in preclinical models and human pilot studies; significant improvements in left ventricular ejection fraction shown in Phase 2 CAST-HF trial at the Medical University of Innsbruck

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Medical University of InnsbruckInnsbruck University Hospital for Cardiac SurgeryNonvasiv Medical GmbH, Konstanz, Germany

Beyond the preview

Go deeper on Heart Regeneration Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heart Regeneration Technologies.

Explore the full profile